Novo Nordisk Analyst Price Targets

Wall Street analyst price targets and consensus rating for Novo Nordisk (NVO).

Price Target Range — 11 Quarters

Analyst Consensus — 12 Analysts

4Buy

6Hold

2Sell

Consensus RatingOverweight# Analysts12Avg. Consensus PT$84Upside to Avg. PT+110.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	BMO Capital	Evan David Seigerman	PT Cut	Market Perform	$47→$40
Sep 11, 2026	Morgan Stanley	Thibault Boutherin	Downgrade	Equal-Weight→Underweight	$40
Mar 2, 2026	Goldman Sachs	James Quigley	Downgrade	Buy→Neutral	$63→$41
Feb 24, 2026	JP Morgan	Richard Vosser	Downgrade	Overweight→Neutral	—
Jan 9, 2026	CICC	—	Initiate	Outperform	$74
Dec 8, 2025	Argus Research	John Eade	Downgrade	Buy→Hold	—
Nov 28, 2025	Goldman Sachs	James Quigley	PT Cut	Buy	$60→$54
Nov 25, 2025	BMO Capital	Evan David Seigerman	PT Cut	Market Perform	$50→$46
Nov 24, 2025	HSBC	Rajesh Kumar	Downgrade	Buy→Hold	—
Oct 27, 2025	Jefferies	Michael Leuchten	Assumes	Underperform	—
Oct 14, 2025	BMO Capital	Evan David Seigerman	PT Raise	Market Perform	$50→$55
Oct 2, 2025	HSBC	Rajesh Kumar	Upgrade	Hold→Buy	$70
Sep 29, 2025	Morgan Stanley	Thibault Boutherin	Downgrade	Equal-Weight→Underweight	$59→$47
Sep 17, 2025	Berenberg	Kerry Holford	Upgrade	Hold→Buy	—
Aug 19, 2025	TD Cowen	Michael Nedelcovych	PT Cut	Buy	$105→$70
Aug 5, 2025	UBS	Matthew Weston	Downgrade	Buy→Neutral	—
Jul 31, 2025	HSBC	Rajesh Kumar	Downgrade	Buy→Hold	—
Jul 30, 2025	Barclays	Emily Field	Downgrade	Overweight→Equal-Weight	—
Jun 18, 2025	TD Cowen	Michael Nedelcovych	Maintained	Buy	$105
Apr 17, 2025	BMO Capital	Evan David Seigerman	Downgrade	Outperform→Market Perform	$105→$64

Analyst Ratings News

PRO
BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40

BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and lowers the price target from $47 to $40.

Benzinga Newsdesk

This Novo Nordisk Analyst Turns Bearish; Here Are Top 4 Downgrades For Friday

Analysts downgraded Novo Nordisk, Chewy, NuScale Power and Atmos Energy, cutting price targets for three companies.

Avi Kapoor

PRO
Morgan Stanley Downgrades Novo Nordisk to Underweight, Maintains Price Target to $40

Morgan Stanley analyst Thibault Boutherin downgrades Novo Nordisk (NYSE:NVO) from Equal-Weight to Underweight and maintains the price target from $40 to $40.

Benzinga Newsdesk

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.

Priya Nigam

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.

Vandana Singh

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

Hims & Hers Health shares tank after disappointing Q1 results. Company raised 2026 revenue outlook. EBITDA outlook was lowered by $25M.

Priya Nigam

Novo Nordisk AS

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Novo Nordisk Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40

This Novo Nordisk Analyst Turns Bearish; Here Are Top 4 Downgrades For Friday

PRO
Morgan Stanley Downgrades Novo Nordisk to Underweight, Maintains Price Target to $40

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

Why Is BioAge Labs Stock Sinking Friday?

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

People Also Watch

People Also Watch

Novo Nordisk AS

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Novo Nordisk Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40

This Novo Nordisk Analyst Turns Bearish; Here Are Top 4 Downgrades For Friday

PROMorgan Stanley Downgrades Novo Nordisk to Underweight, Maintains Price Target to $40

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

Why Is BioAge Labs Stock Sinking Friday?

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

People Also Watch

People Also Watch

PRO
BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40

PRO
Morgan Stanley Downgrades Novo Nordisk to Underweight, Maintains Price Target to $40